Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates

Financial Performance - Novavax reported quarterly earnings of $2.93 per share, significantly exceeding the Zacks Consensus Estimate of $0.71 per share, and compared to a loss of $1.05 per share a year ago, representing an earnings surprise of 312.68% [1] - The company posted revenues of $666.66 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 215.04%, and compared to year-ago revenues of $93.86 million [2] Market Performance - Novavax shares have declined approximately 26% since the beginning of the year, while the S&P 500 has decreased by 4.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.07 on revenues of $149.29 million, and for the current fiscal year, it is $0.84 on revenues of $633.26 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Novavax belongs, is currently ranked in the top 33% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Novavax's stock performance [5]